Compare Charter Communications Inc (CHTR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Charter Communications Inc trades at $150.25 (market cap $18.81B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| CHTR | XBI | |
|---|---|---|
Market Cap | $18.81B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $282.74 | $164.28 |
52-Week Low | $123.31 | $86.92 |
Enterprise Value | $115.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charter Communications (CHTR) trades at $150.25, down 1.99% amid volatile broadband sector pressures. The stock shows mixed technical signals with bullish moving averages but overbought RSI readings. Fundamentally, CHTR maintains strong profitability with 9.05% net margins and attractive valuation at 4.1 P/E, though facing revenue declines and subscriber losses. Recent debt refinancing activities and aggressive buybacks highlight management's focus on capital structure optimization.
Investment outlook remains cautious despite deep value metrics. The 10.6% upside to consensus $166.18 target offers potential, but persistent broadband competition and high debt load ($93.2B) create headwinds. Mobile growth and network investments provide long-term catalysts, yet near-term subscriber trends warrant monitoring for sustained recovery.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
